IL150574A0 - Nucleic acids encoding (poly) peptides having chips activity - Google Patents
Nucleic acids encoding (poly) peptides having chips activityInfo
- Publication number
- IL150574A0 IL150574A0 IL15057401A IL15057401A IL150574A0 IL 150574 A0 IL150574 A0 IL 150574A0 IL 15057401 A IL15057401 A IL 15057401A IL 15057401 A IL15057401 A IL 15057401A IL 150574 A0 IL150574 A0 IL 150574A0
- Authority
- IL
- Israel
- Prior art keywords
- poly
- peptides
- nucleic acids
- acids encoding
- chemotaxis inhibitory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00200068A EP1118663A1 (fr) | 2000-01-07 | 2000-01-07 | Acides nucléiques codant des protéines inhibitrices de la chimiotaxie |
PCT/EP2001/000270 WO2001049711A2 (fr) | 2000-01-07 | 2001-01-08 | Acides nucleiques codant pour des (poly)peptides ayant une activite de chips |
Publications (1)
Publication Number | Publication Date |
---|---|
IL150574A0 true IL150574A0 (en) | 2003-02-12 |
Family
ID=8170896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15057401A IL150574A0 (en) | 2000-01-07 | 2001-01-08 | Nucleic acids encoding (poly) peptides having chips activity |
Country Status (18)
Country | Link |
---|---|
US (2) | US7081513B2 (fr) |
EP (2) | EP1118663A1 (fr) |
JP (1) | JP2003518940A (fr) |
KR (1) | KR20020073496A (fr) |
AT (1) | ATE490324T1 (fr) |
AU (1) | AU3540901A (fr) |
BR (1) | BR0107458A (fr) |
CA (1) | CA2395876A1 (fr) |
DE (1) | DE60143561D1 (fr) |
DK (1) | DK1244790T3 (fr) |
ES (1) | ES2382422T3 (fr) |
HU (1) | HUP0300999A2 (fr) |
IL (1) | IL150574A0 (fr) |
NO (1) | NO20023248L (fr) |
PL (1) | PL356838A1 (fr) |
PT (1) | PT1244790E (fr) |
RU (1) | RU2002120995A (fr) |
WO (1) | WO2001049711A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL345452A1 (en) * | 1998-07-10 | 2001-12-17 | Jari Pharmaceuticals Bv | Chemotaxis-inhibiting protein of staphylococcus |
EP1118663A1 (fr) | 2000-01-07 | 2001-07-25 | Universiteit Utrecht | Acides nucléiques codant des protéines inhibitrices de la chimiotaxie |
US20020086292A1 (en) | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
EP1586583A3 (fr) * | 2004-04-16 | 2005-11-16 | Alligator Bioscience AB (publ) | Composés qui bloquent le récepteur du complément C5a et leur utilisation en thérapie |
EP1778882A2 (fr) | 2004-07-26 | 2007-05-02 | State of Israel, Department of Agriculture, Kimron Veterinary Institute | Nouvelle bacterie et produits pharmaceutiquement actif obtenu a partir de celle-ci |
GB2432366B (en) * | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
GB0607798D0 (en) * | 2006-04-20 | 2006-05-31 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
WO2007144198A2 (fr) * | 2006-06-16 | 2007-12-21 | Umc Utrecht Holding B.V. | INHIBITEURS DU FPLR-1 (FLIPr ET TYPE FLIPr) À UTILISER DANS DES MALADIES IMPLIQUANT DES ÉPISODES INFLAMMATOIRES INDUITS PAR LES AMYLOÏDES ET DES MALADIES MÉDIÉES PAR LE COMPLEXE IMMUNITAIRE |
GB0905790D0 (en) | 2009-04-03 | 2009-05-20 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
US20130034568A1 (en) * | 2010-01-22 | 2013-02-07 | Georgios Hajishengallis | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4772584A (en) | 1986-05-23 | 1988-09-20 | Cleary Paul P | Inhibitor of C5a-mediated chemotaxis |
EP0669989A1 (fr) | 1991-08-22 | 1995-09-06 | Washington University | Sondes de polynucleotide de detection de salmonelle |
US5514555A (en) * | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
PL345452A1 (en) | 1998-07-10 | 2001-12-17 | Jari Pharmaceuticals Bv | Chemotaxis-inhibiting protein of staphylococcus |
JP3722194B2 (ja) * | 1999-05-20 | 2005-11-30 | セイコーエプソン株式会社 | 画像表示システム |
EP1118663A1 (fr) | 2000-01-07 | 2001-07-25 | Universiteit Utrecht | Acides nucléiques codant des protéines inhibitrices de la chimiotaxie |
US6958213B2 (en) * | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
US20020086292A1 (en) * | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
WO2003006048A1 (fr) | 2001-07-11 | 2003-01-23 | Jari Pharmaceuticals B.V. | Combinaison de composes a base de chips (proteine inhibant la chimiotaxie de staphylococcus aureus) |
DE60312507T3 (de) * | 2002-05-17 | 2011-08-18 | Alligator Bioscience Ab | Eine methode zur in vitro molekularen evolution der proteinfunktion |
EP1586583A3 (fr) | 2004-04-16 | 2005-11-16 | Alligator Bioscience AB (publ) | Composés qui bloquent le récepteur du complément C5a et leur utilisation en thérapie |
-
2000
- 2000-01-07 EP EP00200068A patent/EP1118663A1/fr not_active Withdrawn
-
2001
- 2001-01-08 US US10/169,591 patent/US7081513B2/en not_active Expired - Fee Related
- 2001-01-08 IL IL15057401A patent/IL150574A0/xx unknown
- 2001-01-08 PL PL01356838A patent/PL356838A1/xx unknown
- 2001-01-08 RU RU2002120995/13A patent/RU2002120995A/ru unknown
- 2001-01-08 EP EP01907437A patent/EP1244790B1/fr not_active Expired - Lifetime
- 2001-01-08 AT AT01907437T patent/ATE490324T1/de active
- 2001-01-08 CA CA002395876A patent/CA2395876A1/fr not_active Abandoned
- 2001-01-08 HU HU0300999A patent/HUP0300999A2/hu unknown
- 2001-01-08 AU AU35409/01A patent/AU3540901A/en not_active Abandoned
- 2001-01-08 PT PT01907437T patent/PT1244790E/pt unknown
- 2001-01-08 WO PCT/EP2001/000270 patent/WO2001049711A2/fr active Application Filing
- 2001-01-08 DK DK01907437.6T patent/DK1244790T3/da active
- 2001-01-08 ES ES01907437T patent/ES2382422T3/es not_active Expired - Lifetime
- 2001-01-08 DE DE60143561T patent/DE60143561D1/de not_active Expired - Lifetime
- 2001-01-08 BR BR0107458-0A patent/BR0107458A/pt not_active Application Discontinuation
- 2001-01-08 KR KR1020027008742A patent/KR20020073496A/ko not_active Application Discontinuation
- 2001-01-08 JP JP2001550251A patent/JP2003518940A/ja active Pending
-
2002
- 2002-07-04 NO NO20023248A patent/NO20023248L/no not_active Application Discontinuation
-
2006
- 2006-03-08 US US11/370,574 patent/US7388078B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7388078B2 (en) | 2008-06-17 |
AU3540901A (en) | 2001-07-16 |
EP1118663A1 (fr) | 2001-07-25 |
DE60143561D1 (de) | 2011-01-13 |
JP2003518940A (ja) | 2003-06-17 |
EP1244790B1 (fr) | 2010-12-01 |
PT1244790E (pt) | 2011-03-09 |
WO2001049711A3 (fr) | 2001-12-27 |
KR20020073496A (ko) | 2002-09-26 |
PL356838A1 (en) | 2004-07-12 |
HUP0300999A2 (hu) | 2003-07-28 |
ES2382422T3 (es) | 2012-06-08 |
EP1244790A2 (fr) | 2002-10-02 |
NO20023248D0 (no) | 2002-07-04 |
WO2001049711A2 (fr) | 2001-07-12 |
DK1244790T3 (da) | 2011-03-14 |
ATE490324T1 (de) | 2010-12-15 |
NO20023248L (no) | 2002-09-06 |
BR0107458A (pt) | 2002-12-17 |
US20060205655A1 (en) | 2006-09-14 |
US20030175881A1 (en) | 2003-09-18 |
US7081513B2 (en) | 2006-07-25 |
RU2002120995A (ru) | 2004-03-10 |
CA2395876A1 (fr) | 2001-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2257133A1 (fr) | Variantes hyperactives de la desoxyribonuclease i humaine | |
CA2067744A1 (fr) | Recepteur (cr1) c3b/c4b humain | |
WO2007010401A3 (fr) | Il-7 glycosylee, preparation et utilisations | |
MXPA03001984A (es) | Variantes de factor vii de coagulacion humano. | |
DE69635899D1 (de) | Polypeptid, das die differenzierung unterdrueckt | |
WO2002022776A3 (fr) | Variants du facteur vii de coagulation humaine | |
EP1319023B8 (fr) | Peptide de hsp70 stimulant l'activite de cellules tueuses naturelles (nk) et ses utilisations | |
TW200407425A (en) | Human coagulation factor VII polypeptides | |
IL150574A0 (en) | Nucleic acids encoding (poly) peptides having chips activity | |
GB0100551D0 (en) | Protein | |
NZ503235A (en) | Amino-terminally truncated RANTES as chemokine antagonists | |
WO2003088899A3 (fr) | Techniques de production de vecteurs de virus adeno-associes (aav) chimeriques, de composition de vecteurs aav chimeriques et techniques d'utilisation de ceux-ci | |
YU68702A (sh) | Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka | |
DE50010519D1 (de) | Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz | |
AU2003292326A1 (en) | Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser | |
WO2005005630A3 (fr) | Utilisation therapeutique d'inhibiteur de la voie de la lectine, inhibiteur de la voie de la lectine d'origine staphylococcique dans des maladies inflammatoires | |
IL151647A0 (en) | Novel lhrh-antagonists, production and use thereof as medicament | |
IL169256A (en) | Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it | |
WO2001053324A3 (fr) | Nouveaux peptides haptotactiques | |
CA2250433A1 (fr) | Dnase ii humaine | |
EP1782823A3 (fr) | Acides nucléiques et peptides de IL-21 | |
WO2001092301A3 (fr) | Placc, nouvelle chimiokine c-c humaine isolee du placenta | |
WO2002034882A3 (fr) | Gene de regulation de l'apoptose | |
JP2002348254A5 (fr) |